Routine Systematic Prostate Biopsies not Replaced by Magnetic Resonance Imaging-Targeted Biopsy
Rev. invest. clín
; 74(4): 212-218, Jul.-Aug. 2022. tab, graf
Article
em En
|
LILACS-Express
| LILACS
| ID: biblio-1409583
Biblioteca responsável:
MX1.1
ABSTRACT
ABSTRACT Background:
Multiparametric magnetic resonance imaging improves the performance of prostate cancer (PCa) diagnostics through a better selection of patients.Objectives:
The aim of the study was to study the detection rate (DR) of systematic and targeted cognitive biopsies in a cohort with the previous negative systematic biopsies. A secondary objective was to describe the value of prostate-specific antigen density (PSAd) in the detection of clinically significant PCa (CSPCa).Methods:
We designed a prospective, single-center, and comparative study to determine the DR of systematic and targeted cognitive biopsies. The clinical and pathological characteristics of each patient were described.Results:
A total of 111 patients with Prostate Imaging Reporting and Data System lesions > 3 were included in the study. PCa was detected in 41.4% (46 of 111 patients); 42 (91.3%) were detected by systematic biopsy and 30 (65.2%) by targeted biopsy. CSPCa was detected in 26 (23.4%), 23 (88.5%) by systematic biopsy, and 21 (76.9%) by targeted biopsy. PSAd > 0.15 was directly associated with CSPCa.Conclusion:
The detection of PCa by systematic biopsy in this series was higher than 80%; hence, its routine use should not be replaced by targeted biopsy, since it continues to be the cornerstone of the diagnosis in patients with prior negative biopsies.
Texto completo:
1
Índice:
LILACS
Idioma:
En
Revista:
Rev. invest. clín
Assunto da revista:
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article